Showing results (151-160 of 162) with videos related to
Sort By:
Pageof 17
Journal of the National Cancer Institute|October 18, 2024
Validation of a breast cancer assay for radiotherapy omission: an individual participant data meta-analysisPer Karlsson, Anthony Fyles, S Laura Chang, et al.Journal of the National Comprehensive Cancer Network : JNCCN|January 12, 2023
Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast CancerMatteo Lambertini, Marcello Ceppi, Richard A Anderson, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2021
Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO StudyNicholas C Turner, Judith Balmaña, Coralie Poncet, et al.Lancet (London, England)|June 11, 2019
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trialHelena M Earl, Louise Hiller, Anne-Laure Vallier, et al.Journal of the National Cancer Institute|November 9, 2014
Maastricht Delphi consensus on event definitions for classification of recurrence in breast cancer researchMartine Moossdorff, Lori M van Roozendaal, Luc J A Strobbe, et al.The New England Journal of Medicine|October 9, 2016
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast CancerGabriel N Hortobagyi, Salomon M Stemmer, Howard A Burris, et al.The New England Journal of Medicine|June 6, 2022
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast CancerShanu Modi, William Jacot, Toshinari Yamashita, et al.JAMA|January 30, 2025
Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA/IMpassion030 Randomized Clinical TrialMichail Ignatiadis, Andrew Bailey, Heather McArthur, et al.The Lancet. Oncology|June 1, 2026
International disruptions to cancer diagnosis and stage at presentation during the COVID-19 pandemic in 2020: an International Cancer Benchmarking Partnership (ICBP) population-based studyEileen Morgan, Aude Bardot, Oliver Langselius, et al.British Journal of Cancer|July 7, 2023
Thromboxane biosynthesis in cancer patients and its inhibition by aspirin: a sub-study of the Add-Aspirin trialNalinie Joharatnam-Hogan, Duaa Hatem, Fay H Cafferty, et al.Pageof 17